A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- and Placebo-Controlled Polysomnography Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Subjects With Insomnia Disorder
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2018
At a glance
- Drugs Seltorexant (Primary) ; Zolpidem
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; Minerva Neurosciences
- 11 Dec 2017 Planned number of patients changed to 360.
- 06 Dec 2017 According to a Minerva Neurosciences media release, first patient has been enrolled.
- 06 Dec 2017 Status changed from planning to recruiting, according to a Minerva Neurosciences media release.